At day 49 after the original CT26-EphA2 tumor implant, CR mice were re-challenged with syngeneic CT26-EphA2 cells in the contralateral hind flank, and tumor growth was monitored (Fig. 5A). This evidence concerns the gene EPHA2 and neoplasm.